Unclassified · Medical Literature

[Articles] Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial

Authors
Migbaru Keffale Bezabih, Tadesse Misganaw, Legesse Alamerie Ejigu, Stefano Rosillo, Hiwot Teka, Dawit Hailu Alemayehu, Bethlehem Adnew, Bereket Hailegiorgis, Samuel Girma, Mekonnen Tadesse, Fikregabrail Aberra Kassa, Mikiyas Gebremichael, Desalegn Abeje Tefera, Wakweya Chali, Sinknesh Wolde Behaksera, Lina Alemayehu, Jimma Dinsa Deressa, Melat Abdo, Getnet Habtamu, Addisu Gizat, Woyneshet Gelaye Yalew, Tadesse Hailu Jember, Molalegne Bitew, Peter Mumba, Mateusz M Plucinski, Samaly Souza, Dhruviben S Patel, Eldin Talundzic, Hiwot Solomon Taffese, Kebede Etana Geleta, Degu Mehari, Gudissa Assefa Bayissa, Teun Bousema, Jon Eric Tongren, Jimee Hwang, Fitsum G Tadesse
Journal
The Lancet Microbe
Publication date
2026-06-08
Source
rss_lancet_mic
Original record ID
270267
Summary status
error
Analysis status
error
Original last updated
2026-08-17T08:00:03.000Z

Open original source

Abstract

Our findings reinforce the continued use of artemether–lumefantrine plus primaquine for treating uncomplicated P falciparum malaria. Pyronaridine–artesunate plus primaquine also shows promise as an alternative regimen. Continued surveillance remains essential to safeguarding both therapeutic effectiveness and diagnostic accuracy.